Please login to the form below

Not currently logged in

Sepracor's epilepsy drug cuts seizures

Sepracor has said its esclicarbazepine acetate drug causes a significant reduction in the frequency of seizures
Sepracor has said that results of its randomised, double-blind trials involving 1,049 patients show that compared to a placebo, patients given its esclicarbazepine acetate drug (in either 800mg or 1200mg doses) experience a significant reduction in the frequency of seizures.

The phase III trials involved patients, who despite being treated with epilepsy drugs, experienced four or more partial seizures per month. Over a 12-week period, patients receiving the 800mg dosage showed a 35.4 per cent relative reduction in seizure frequency. Patients receiving the 1200mg dose showed a 38.8 per cent reduction.

In an open-label follow up study lasting 52 weeks, patients who were given esclicarbazepine acetate showed statistically significant improvements in quality of life.

Esclicarbazepine acetate is designed to be used in combination with other anti-epileptic drugs. It is a sodium channel blocker that works by blocking electrical signals in the brain to reduce the frequency of partial-onset seizures.

19th June 2008


Featured jobs

Subscribe to our email news alerts


Add my company
Market Access Transformation

MAT offers an information exchange called Rapid Payer Response that allows healthcare stakeholders to secure immediate, global, expert insight and...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...